ASTRAZENAstraZeneca Pharma India Limited
Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-10-26 (delayed ~30 min in market hours)
AstraZeneca Pharma India Limited, a biopharmaceutical company, manufactures, markets, and trades in pharmaceutical products in India and internationally. It provides medicines for cardiovascular, renal, metabolic, and immunological conditions; oncology medicines under the TAGRISSO, Lynparza, ENHERTU, IMFINZI, and Zoladex brand names; rare diseases medicines under the Koselugo brand name; and respiratory medicines under the Symbicort and Fasenra brand names. The company also offers medicines for diabetes; and clinical trial services. The company has a strategic collaboration with Leica Biosystems and Daiichi Sankyo Company, Limited for the development of an immunohistochemistry assay and an image analysis algorithm for the TROP2 NMR biomarker in non-small cell lung cancer. The company was incorporated in 1979 and is based in Bengaluru, India. AstraZeneca Pharma India Limited is a subsidiary of AstraZeneca Pharmaceuticals AB.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on ASTRAZEN — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
The picture
- • Revenue growth: 29.7% YoY
- • ROE: 21.5%
- • ROCE: 23.7%
- • MACD: bullish
- • Trend strength (ADX): 58
- • Bollinger position: 59% of band
Bull case
- • Revenue growth: 29.7% YoY
- • ROE: 21.5%
- • ROCE: 23.7%
- • MACD: bullish
Bear case
- • Profit growth: -32.1% YoY
- • Valuation vs sector: P/E 89.6 vs sector 35.5
- • RSI: 41
- • Price vs EMA21: below
Key risks
- • Momentum is fading versus the broader market
- • Profit growth: -32.1% YoY
- • Valuation vs sector: P/E 89.6 vs sector 35.5
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹168.48). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.